A5045550662- Antibiotics Pharmacokinetics and Efficacy
- Antibiotic Resistance in Bacteria
- Antibiotic Use and Resistance
- Pneumonia and Respiratory Infections
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Streptococcal Infections and Treatments
- Pharmaceutical and Antibiotic Environmental Impacts
- Urinary Tract Infections Management
- Clostridium difficile and Clostridium perfringens research
- Global Maternal and Child Health
- Pharmaceutical Economics and Policy
- Infective Endocarditis Diagnosis and Management
- Drug-Induced Adverse Reactions
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
- Respiratory and Cough-Related Research
- Neutropenia and Cancer Infections
- Orthopedic Infections and Treatments
- Drug Transport and Resistance Mechanisms
- Antifungal resistance and susceptibility
- Evolution and Genetic Dynamics
- Pneumocystis jirovecii pneumonia detection and treatment
- Nosocomial Infections in ICU
- Otolaryngology and Infectious Diseases
Uppsala University
2013-2024
Public Health Agency of Sweden
2015-2017
Uppsala University Hospital
1999-2011
Swedish Armed Forces
2007-2010
Swedish Institute
2001-2008
Ratio
2007
University of Oslo
2006-2007
Linköping University
2007
Oslo University Hospital
2006
Karolinska Institutet
2005
Abstract In Europe, antimicrobial resistance has been monitored since 1998 by the European Antimicrobial Resistance Surveillance System (EARSS). We examined relationship between penicillin nonsusceptibility of invasive isolates Streptococcus pneumoniae (an indicator organism) and antibiotic sales. Information was collected on 1998-99 data for S. to penicillin, based surveillance from EARSS outpatient sales during 1997 beta-lactam antibiotics macrolides. Our results show that in Europe is...
ABSTRACT Colistin is used to treat infections caused by multidrug-resistant gram-negative bacteria (MDR-GNB). It administered intravenously in the form of colistin methanesulfonate (CMS), which hydrolyzed vivo active drug. However, pharmacokinetic data are limited. The aim present study was characterize pharmacokinetics CMS and a population critically ill patients. Patients receiving for treatment MDR-GNB were enrolled study; however, patients renal replacement therapy excluded. at dose 3...
We have failed to keep pace with the ability of many pathogens develop resistance antibiotics. Progress has recently been made on 4 10 key challenges ensuring that antibiotics retain an effective role in medicine, but more daunting remain.
Foreign travel has been suggested to be a risk factor for the acquisition of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. To our knowledge, this not previously demonstrated in prospective study. Healthy volunteers traveling outside Northern Europe were enrolled. Rectal swabs and data on potential travel-associated factors collected before after traveling. A total 105 Four them did complete study, one participant carried ESBL-producing Escherichia coli travel....
A pharmacokinetic-pharmacodynamic (PKPD) model that characterizes the full time course of in vitro time-kill curve experiments antibacterial drugs was here evaluated its capacity to predict previously determined PK/PD indices. Six (benzylpenicillin, cefuroxime, erythromycin, gentamicin, moxifloxacin, and vancomycin), representing a broad selection mechanisms action PK PD characteristics, were investigated. For each drug, dose fractionation study simulated, using wide range total daily doses...
ABSTRACT A previous pharmacokinetic study on dosing of colistin methanesulfonate (CMS) at 240 mg (3 million units [MU]) every 8 h indicated that has a long half-life, resulting in insufficient concentrations for the first 12 to 48 after initiation treatment. loading dose would therefore be beneficial. The aim this was evaluate CMS and pharmacokinetics following 480-mg (6-MU) critically ill patients explore bacterial kill use different regimens obtained by predictions from...
A concerted global response is needed to tackle rising rates of antibiotic resistance, say Otto Cars and colleagues
ObjectivesThe worldwide rapid increase in antibiotic-resistant bacteria has made efforts to prolong the lifespan of existing antibiotics very important. Antibiotic resistance often confers a fitness cost bacterium. Resistance may thus be reversible if antibiotic use is discontinued or reduced. To examine this concept, we performed 24 month voluntary restriction on trimethoprim-containing drugs Kronoberg County, Sweden.
Increasing use of antibiotics and rising levels bacterial resistance to are a challenge global health development.Successful initiatives for containing the problem need be communicated disseminated.In Sweden, rapid spread resistant pneumococci in southern part country triggered formation Swedish strategic programme against antibiotic resistance, also known as Strama, 1995.The creation was an important starting point long-term coordinated efforts tackle country.This paper describes main...
ABSTRACT Combination therapy is recommended for infections with carbapenemase-producing Klebsiella pneumoniae . However, limited data exist on which antibiotic combinations are the most effective. The aim of this study was to find effective against metallo-beta-lactamase-producing K. (MBL-KP). Two VIM- and two NDM-producing strains, all susceptible colistin, were exposed antibiotics at clinically relevant static concentrations during 24-h time-kill experiments. Double- triple-antibiotic...